Biologics CDMO Market Outlook:
Biologics CDMO Market size was valued at USD 21.02 billion in 2025 and is likely to cross USD 73.27 billion by 2035, registering more than 13.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of biologics CDMO is assessed at USD 23.54 billion.
The biopharmaceutical industry experienced rapid expansion, particularly in emerging markets, and is significantly prospecting the pharma sector. For instance, the biopharma sector in India held a 49.0% stake in the bioeconomy in 2022, according to the Biotechnology Industry Research Assistance Council. An estimated USD 39.4 billion was the segments total economic contribution. Further, rising healthcare needs and biotech advancements drive demand for recombinant therapies, contributing to contract processing growth globally and increasing the capacity to manufacture monoclonal antibodies and gene therapies at an industrial scale. This expansion allows contract biomanufacturing to meet regional and global needs, driving continued escalation in the biologics CDMO market.
Additionally, the growing trend towards personalized medicine, driven by advancements in gene-based treatments and targeted interventions, is creating a need for more customized and smaller batches of biologicals. These remedies require highly customized processes to ensure precision and efficacy. CDOs have the expertise and facilities to produce these smaller, proficient batches, making them the perfect choice for pharma companies. As more biopharmaceutical companies turn to contract manufacturers for this specialized development, the demand for these services continues to rise, contributing to the surge of the market.
